Top Markets
#1 ADO Protocol ADO Protocol +329.72%
#2 GoPlus Security GoPlus Security +51.65%
#3 Nockchain Nockchain +47.38%
#4 Tutorial Tutorial +42.31%
#5 Starpower Starpower +33.22%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +30.91%
#7 The Black Bull The Black Bull +27.75%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +17.77%
#10 Verus Coin Verus Coin +16.89%
Coin of the day
ADO Protocol ADO Protocol
Instellingen
Taal
DUTCH
Valuta
USD
Thema
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rang in aandelen #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aandeelprijs
$5.60
Marktkapitalisatie
$8.18M
Verandering (1 dag)
1.45%
Verandering (1 jaar)
10.02%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Categorie

Healthcare
Winst voor CNS Pharmaceuticals, Inc. (CNSP)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van CNS Pharmaceuticals, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van CNS Pharmaceuticals, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE